Protein Discovery

Mass spectrometry has taken a leading position as the technology of choice for analyzing the human proteome, and will soon become a dominant analytical tool in clinical diagnostics, replacing some clinical assays and augmenting others. The expanding use of mass spectrometry is driven by the analytical power of the technique, new and increasingly specialized commercial instrumentation, the data requirements of systems biology, and serious efforts to improve drug discovery efficiency and implement stratified medicine.

The three basic elements of mass spectrometry based analysis are: sample preparation, production of mass spectra, and analysis. At the head of the process, sample preparation defines and limits both throughput and data quality. In human tissue proteomics, for example, slow rates of sample preparation prevent researchers from producing the large amounts of high-quality mass spectrometry data needed for efficient biomarker discovery and validation, even though the downstream instrumentation and informatics solutions required are available, capable, and scalable.

Protein Discovery is focused on developing and commercializing sample preparation technologies that enable clinical utilization of the immense resolving power of mass spectrometry. PPS Silent® Surfactant replaces conventional protein extraction and solubilization detergents that either interfere with mass spectrometry or cause other problems in use at the lab bench. And the Passport™ 1200 Sample Prep Station exploits recent advances in polymer chemistry to automate and accelerate clinical sample preparation for mass spectrometry.

Protein Discovery has assembled a focused intellectual property portfolio which provides a stable foundation for the company's R&D, engineering, and commercialization programs. The company is privately held and is funded by private capital investment and income from operations.

TOP